NanoViricides has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $3.8 million in gross proceeds before fees and expenses. The offering includes 2.52 million common shares or pre-funded warrants, along with accompanying warrants to purchase an additional 2.52 million shares. Each warrant has an exercise price of $1.75 per share and a 5.5-year term. The transaction is expected to close on or about July 27, 2026. Shares of NanoViricides fell 11% in premarket trading.
NanoViricides IncCompany announces a dilutive registered direct offering of shares and warrants, causing stock to fall 11% in premarket.